|
 The agreement will allow MedImmune to combine its experimental
immunotherapy drugs with Omnis’ virus program, which is currently in
initial Phase I clinical testing. Financial terms were not
disclosed.
Oncolytic viruses are designed to target tumor cells with the
killing potency of viruses.
(Reporting by Ben Hirschler, editing by Louise Heavens)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
